Lupin's Pithampur facility passes UK MHRA inspection

27 Mar 2023 , 09:44 AM

Lupin Limited, a leading pharmaceutical company, has declared that its Pithampur facility in India has passed the inspection conducted by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA).

Nilesh Gupta, the Managing Director of Lupin, expressed his pride in the successful inspection of the Pithampur site by the MHRA. He emphasized the company’s strong dedication to maintaining high standards of quality and compliance. 

The Pithampur site plays a crucial role in the production of various products such as oral solid, inhalation, dermatology, high potent, and oral contraceptive products. Gupta believes that ensuring the facility’s strict adherence to regulatory standards is essential to the company’s continued success.

Further, in a separate release Lupin also informed that USFDA has completed a Post-Marketing Adverse Drug Experience (PADE) inspection of its operations. USFDA closed the inspection with no observations. From March 20 to March 24, 2023, the inspection was carried out at Lupin’s global pharmacovigilance group in Mumbai.

At around 9.39 AM, Lupin was trading 2.12% higher at Rs653.55, against the previous close of Rs640 on NSE. The counter opened at Rs644.

For feedback and suggestions, write to us at [e-mail]